Vertex adds to deal spree with $950m for biotech seeking diabetes cure 04-Sep-2019 By Ben Hargreaves Vertex is set to acquire Semma, which is developing a stem cell curative treatment for type 1 diabetes and expects the deal to ‘rapidly advance’ its potential therapy.